Aerovate Therapeutics Stock Price on January 3, 2025

AVTE Stock  USD 2.51  0.04  1.57%   
If you're considering investing in Aerovate Stock, it is important to understand the factors that can impact its price. As of today, the current price of Aerovate Therapeutics stands at 2.51, as last reported on the 26th of March, with the highest price reaching 2.55 and the lowest price hitting 2.51 during the day. Aerovate Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0345, which signifies that the company had a -0.0345 % return per unit of risk over the last 3 months. Aerovate Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Aerovate Therapeutics' Mean Deviation of 1.31, insignificant risk adjusted performance, and Standard Deviation of 1.74 to double-check the risk estimate we provide.
  
At present, Aerovate Therapeutics' Liabilities And Stockholders Equity is projected to increase significantly based on the last few years of reporting. The current year's Capital Stock is expected to grow to 3,622, whereas Other Stockholder Equity is forecasted to decline to about 180.7 M. . At present, Aerovate Therapeutics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 1.04, whereas Price To Operating Cash Flows Ratio is forecasted to decline to (1.12). Aerovate Stock price history is provided at the adjusted basis, taking into account all of the recent filings.

Sharpe Ratio = -0.0345

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsAVTE

Estimated Market Risk

 1.8
  actual daily
16
84% of assets are more volatile

Expected Return

 -0.06
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.03
  actual daily
0
Most of other assets perform better
Based on monthly moving average Aerovate Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aerovate Therapeutics by adding Aerovate Therapeutics to a well-diversified portfolio.
Price Book
0.9038
Book Value
2.637
Enterprise Value
-15.4 M
Enterprise Value Ebitda
(9.33)
Shares Float
12 M

Related Headline

AN2 Therapeutics Headline on 3rd of January 2025

Biden Blocks 14.1 Billion U.S. Steel Sale Tech Giants Lift Nasdaq 1.46

Aerovate Therapeutics Valuation on January 3, 2025

It is possible to determine the worth of Aerovate Therapeutics on a given historical date. On January 3, 2025 Aerovate was worth 2.71 at the beginning of the trading date compared to the closed value of 2.68. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Aerovate Therapeutics stock. Still, in general, we apply an absolute valuation method to find Aerovate Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aerovate Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Aerovate Therapeutics' related companies.
 Open High Low Close Volume
  2.68    2.71    2.66    2.69    154,171  
01/03/2025
  2.71    2.73    2.66    2.68    311,813  
  2.68    2.71    2.68    2.70    280,556  
Backtest Aerovate Therapeutics  |  Aerovate Therapeutics History  |  Aerovate Therapeutics Valuation   PreviousNext  
Open Value
2.71
2.68
Closing Value
8.11
Upside

Aerovate Therapeutics Trading Date Momentum on January 3, 2025

On January 06 2025 Aerovate Therapeutics was traded for  2.70  at the closing time. The top price for the day was 2.71  and the lowest listed price was  2.68 . The trading volume for the day was 280.6 K. The trading history from January 6, 2025 was a factor to the next trading day price growth. The overall trading delta against the next closing price was 0.75% . The overall trading delta against the current closing price is 5.97% .

Aerovate Therapeutics Fundamentals Correlations and Trends

By evaluating Aerovate Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Aerovate Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Aerovate financial account trend analysis is a perfect complement when working with valuation or volatility modules.

About Aerovate Therapeutics Stock history

Aerovate Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Aerovate is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Aerovate Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Aerovate Therapeutics stock prices may prove useful in developing a viable investing in Aerovate Therapeutics
Last ReportedProjected for Next Year
Common Stock Shares Outstanding28.6 M28 M
Net Loss-20.7 M-19.7 M

Aerovate Therapeutics Quarterly Net Working Capital

80.29 Million

Aerovate Therapeutics Stock Technical Analysis

Aerovate Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Aerovate Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Aerovate Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Price Boundaries

Aerovate Therapeutics Period Price Range

Low
March 26, 2025
0.00  NaN%
High

 0.00 

     

 0.00 

Aerovate Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.

Aerovate Therapeutics March 26, 2025 Market Strength

Market strength indicators help investors to evaluate how Aerovate Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aerovate Therapeutics shares will generate the highest return on investment. By undertsting and applying Aerovate Therapeutics stock market strength indicators, traders can identify Aerovate Therapeutics entry and exit signals to maximize returns

Aerovate Therapeutics Technical and Predictive Indicators

Predictive indicators are helping investors to find signals for Aerovate Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Aerovate Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Aerovate to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.

Complementary Tools for Aerovate Stock analysis

When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Global Correlations
Find global opportunities by holding instruments from different markets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years